Drug Profile
Midodrine - GE Healthcare
Alternative Names: Amatine; Gudon; Gutron; Metligine; Midodrine HCl; Midon; ProAmatine; ST 1085; TS 701Latest Information Update: 21 Oct 2021
Price :
$50
*
At a glance
- Originator GE Healthcare
- Developer Myungmoon Pharm; Shire Pharmaceuticals Group; Taisho Pharmaceutical; Takeda
- Class Antihypotensives; Ethanolamines; Small molecules
- Mechanism of Action Alpha adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Orthostatic hypotension; Urinary incontinence
- No development reported Chronic fatigue syndrome
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 29 Mar 2012 Shire initiates two postmarketing clinical trials for Orthostatic hypotension
- 02 Dec 2011 Shire and the US FDA Center for Drug Evaluation and Research reach an agreement to conduct two postmarketing clinical trials for Orthostatic hypotension